

WD

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 09/446,543  
Filed: 12/20/1999  
1<sup>st</sup> Inventor: HINUMA, S  
For: Prolactin Secretion Modulator  
Atty. Dkt. No. 2472 USOP

Art Unit: 1653

Examiner: S. TU

Allowed:

Batch:

Paper No. FEB 12 2001



RECEIVED #

10/13

kd

3-2401

Submission of Replacement Sequence Listing  
and CRF of Sequence Listing Under 37 CFR §§1.821-1.825

TECH CENTER 1600/2500

Assistant Commissioner for Patents  
Washington, D.C. 20231  
Sir:

In reply to the Examiner's Communication mailed January 10, 2001, requiring compliance with the Sequence Listing rules, Applicants herewith submit a reformatted written copy of the Sequence Listing for the above-identified case, and a Computer Readable File (CRF) of the same Sequence Listing named "2472USOP" which is in IBM DOS Text format on a 3.5" IBM PC/AT computer disk, prepared using the USPTO PatentIn computer program version 3.0.

The Sequence Listing, herewith submitted replaces the previously filed sequence listing and is identical in content to the previously submitted sequence listing. This substitute sequence listing contains no new matter, only such information as was previously filed as part of the specification and with the addition of the currently assigned application information.

The undersigned hereby certifies that the content of the paper and CRF copies are the same in that the information recorded in the computer readable form is identical to the written sequence listing.

Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, he is respectfully requested to call applicants' attorney at (847) 383-3372.

Respectfully submitted,

Dated: February 2, 2001

Philippe Y. Riesen, Reg. No. 35,657  
Mark Chao, Ph.D., Reg. No. 37,293  
Attorney for Applicants  
Customer No. 23115

TECH CENTER 1600/2500

MAR 19 2001

RECEIVED

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821-1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: \_\_\_\_\_

## Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.822(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216


For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**



RECEIVED

FEB 12 2001

TECH CENTER 1600/2900

RECEIVED  
FEB 16 2001  
TECH CENTER 1600/2900